What is Replimune?
Replimune Group, headquartered in Massachusetts, is a prominent biotechnology company dedicated to developing novel immunotherapies for cancer. The company's core focus lies in enhancing the anti-tumor effects of patient-specific immunotherapies and bolstering the immune system's response. This strategic approach positions Replimune at the forefront of oncology innovation, aiming to provide more effective and targeted treatments for patients battling various forms of cancer. The company's commitment to advancing cancer therapy through cutting-edge research and development is a key driver of its market presence.
How much funding has Replimune raised?
Replimune has raised a total of $376M across 5 funding rounds:
Series A
$30M
Series B
$55M
Stock Offering
$111M
Stock Offering
$80M
Stock Offering
$100M
Series A (2015): $30M with participation from Omega Funds, Atlas Ventures, and Forbion
Series B (2017): $55M led by Forbion, Atlas Venture, Leerink Partners, Omega Funds, Cormorant Asset Management, Bain Capital, Redmile Group, and Foresite Capital
Stock Issuance/Offering (2018): $111M supported by Undisclosed
Stock Issuance/Offering (2019): $80M featuring Undisclosed
Stock Issuance/Offering (2020): $100M backed by Undisclosed
Key Investors in Replimune
Forbion
Forbion is a global life sciences venture capital firm that invests across multiple fund strategies covering all stages of pharmaceutical drug development, with a primary focus on innovative therapeutics companies in Europe and North America.
Atlas Venture
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
Omega Funds
Omega Funds is focused on investing in exceptional founders and entrepreneurs, as well as impactful products and platforms across various therapeutic areas, including oncology, immunology, and precision medicine.
What's next for Replimune?
The recent major strategic investment in Replimune indicates a strong validation of its therapeutic pipeline and market potential. This capital infusion is expected to accelerate the company's research and development initiatives, potentially enabling faster clinical trial progression and broader market penetration. As a company operating in the dynamic field of cancer immunotherapy, Replimune's strategic financing positions it for significant growth and the potential to bring life-changing treatments to patients. The company's trajectory suggests a focus on scaling operations and advancing its lead candidates through critical development milestones.
See full Replimune company page
